Type of PTM # of patients with tumors (% incidence)

Reference Organ txpt # pts #HT #PTM Organ site H&N Skin (incl. KS) HLM incl. PTLD NCNL tumor
Sampaio [3] SOT 193,905 - 7,897 (4.1%) - NR 1,645 (20.8%) 6,247(79.2%)
  HT 16,511 - 1,073 (6.5%) - NR 172 (16.0%) 901(84.0%)
Engels [4] SOT 175,732 - 10,656 (6.1%) - NR 1,599 (15%) 9057(85%)
  HT 17,593 - NR - NR 267(37%) 462(63%)
Serraino [6] SOT 2,875 - 222(7.7%) - KS 39(17%) 42(19%) 141(64%)
  HT 682 - 95(14%) - KS 11(12%) 22(23%) 62(65%)
Krynitz [8] SOT 10,476 557 1,610(15.3%) - 668(41%) 173(11%) 769(48%)
Collett [9] SOT 37,617 3609 5,706(15.1) - 3,276(57%) 444(8%) 1986(35%)
Adami [10] SOT 5,931 236 692 (11.6%) - 292 (42%) 61(9%) 339(49%)
Rabinovics [11] SOT 2,817 11 460 (16.3%) 175(6.1%) 163 (93%) NR 12(7%)
Deeb [12] SOT 3,639 NR NR 95(2.6%) 78(82% ) NR 17(18%)
  HT - NR NR 18 16(21%) NR NR 2(12%)
Lott [13] SOT - NR - - 193 (2.7%) NR NR
  HT - NR 59 - 59 (31%) NR NR
PTM, posttransplant malignancy, txpt transplanted, H&N head & neck, KS Kaposi’s sarcoma, HLM hematolymphoid malignancy, NCNL, non-cutaneous non-lymphomatous, SOT, solid organ transplant, HT heart transplant, NR, not reported
Table 1: Incidence of de novo malignancy in SOT recipients.